The first, a LNP system for intravenous administration, is exemplified by Patisiran, which targets transthyretin (TTR) mRNA to treat hereditary transthyretin amyloidosis (hATTR) [137]. This evidence concerns the gene TTR and familial amyloid neuropathy.